Hironori Kikkawa
Shibuya, 1518589, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan.
Journal: Future oncology (London, England)
Published: August 22, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan.
Journal: JTO clinical and research reports
Published: January 04, 2023
Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Journal: Cancer science
Published: July 28, 2022
Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.
Journal: JTO clinical and research reports
Published: October 07, 2020
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Journal: Future oncology (London, England)
Published: September 22, 2020
Inhibitory effect of ergosterol on bladder carcinogenesis is due to androgen signaling inhibition by brassicasterol, a metabolite of ergosterol.
Journal: Journal of natural medicines
Published: May 01, 2020
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Journal: Advances in therapy
Published: April 06, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026